EGFR and neoplasm: Treatments are selected largely without regard for tumour mutation profiles, although recent evidence linking KRAS mutation with poor response to EGFR mAb (Amado et al, 2008; Karapetis et al, 2008; Lievre et al, 2008) now influences decisions in the clinic.